Public Employees Retirement System of Ohio Has $404,000 Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Public Employees Retirement System of Ohio lowered its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 30.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,110 shares of the medical instruments supplier’s stock after selling 30,000 shares during the quarter. Public Employees Retirement System of Ohio owned 0.09% of OraSure Technologies worth $404,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in OraSure Technologies by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock valued at $32,000,000 after purchasing an additional 64,367 shares during the period. Earnest Partners LLC increased its position in OraSure Technologies by 5.2% during the 1st quarter. Earnest Partners LLC now owns 5,123,334 shares of the medical instruments supplier’s stock valued at $34,736,000 after purchasing an additional 251,955 shares during the period. State Street Corp increased its position in OraSure Technologies by 1.9% during the 2nd quarter. State Street Corp now owns 3,440,307 shares of the medical instruments supplier’s stock valued at $9,323,000 after purchasing an additional 63,392 shares during the period. Dimensional Fund Advisors LP increased its position in OraSure Technologies by 6.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,156,930 shares of the medical instruments supplier’s stock valued at $21,405,000 after purchasing an additional 205,126 shares during the period. Finally, Neuberger Berman Group LLC increased its position in OraSure Technologies by 8.7% during the 3rd quarter. Neuberger Berman Group LLC now owns 2,953,375 shares of the medical instruments supplier’s stock valued at $11,214,000 after purchasing an additional 236,827 shares during the period. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Stock Performance

OraSure Technologies stock opened at $6.14 on Thursday. The stock has a market capitalization of $469.77 million, a price-to-earnings ratio of 8.53 and a beta of 0.17. OraSure Technologies, Inc. has a 52-week low of $4.38 and a 52-week high of $8.45. The stock’s 50 day moving average price is $7.11 and its two-hundred day moving average price is $6.81.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.09. The firm had revenue of $75.88 million for the quarter, compared to analysts’ expectations of $74.13 million. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The company’s revenue for the quarter was down 38.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.21 EPS. On average, equities research analysts forecast that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

Analysts Set New Price Targets

Separately, Citigroup increased their target price on shares of OraSure Technologies from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Monday, December 11th.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.